- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04098887
Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma
September 11, 2020 updated by: Washington University School of Medicine
A Phase I Trial of Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma
Unresectable (including metastatic) conventional chondrosarcoma requires high dose radiation for local control.
Radiation Oncologists have traditionally used long radiation courses and concern for toxicity to surrounding organs at risk.
Stereotactic body radiation therapy (SBRT) has the ability to deliver high doses of radiation in a manner that may improve clinical response but has size limitations.
SBRT delivered with lattice radiotherapy (LRT) may safely dose escalate smaller portions of the tumor and also provide improved cancer control.
This study is to evaluate the safety and initial efficacy of this treatment approach.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically confirmed conventional chondrosarcoma.
- At least one, large targetable lesion defined as: 1 lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 45 mm with radiographic imaging or with calipers by clinical exam.
- Deemed metastatic and/or unresectable by multidisciplinary review. Patients with prior resection with gross residual disease that are subsequently deemed ineligible for further resection are allowed.
- Patients that have had prior chemotherapy are allowed
- At least 14 years of age
- ECOG performance status ≤ 2
Normal bone marrow and organ function as defined below:
- Leukocytes ≥ 3,000/mcL
- Absolute neutrophil count ≥ 1,500/mcl
- Platelets ≥ 100,000/mcl
- Radiotherapy is known to be teratogenic. For this reason women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 6 months after completion of the study
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
- Dedifferentiated chondrosarcoma and extra-skeletal myxoid chondrosarcoma are excluded.
- Patients with greater than 5 measurable metastatic lesions as determined by multidisciplinary review are excluded
- Prior radiotherapy that overlaps with any planned site of protocol radiotherapy.
- Currently receiving any systemic cancer therapy agents. Systemic therapy prior to radiotherapy or planned after radiotherapy delivery are allowed at the discretion of the treating radiation oncologist.
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 20 days of study entry.
- Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended. Recommend exclusion of specific ART agents based on predicted drug-drug interactions (i.e. for sensitive CYP3A4 substrates, concurrent strong CYP3A4 inhibitors (ritonavir and cobicistat) or inducers (efavirenz) should be contraindicated).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lattice stereotactic body radiation therapy
Patients with up to 10 chondrosarcoma lesions will undergo radiotherapy to all sites of disease.
For lesions less than 4.5 cm, traditional SBRT will be used.
For sites 4.5 cm or greater, Lattice SBRT will be used.
For Lattice SBRT, radiotherapy will be prescribed to 20 Gy in 5 fractions delivered every other day with a LATTICE simultaneous integrated boost (SIB) to 66.7 Gy in 5 fractions.
|
For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV_2000 and PTV_6670, respectively).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment related grade 3 or higher non-hematologic adverse events
Time Frame: From start of treatment through 90 days post-treatment (approximately 3.5 months)
|
-As scored by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5
|
From start of treatment through 90 days post-treatment (approximately 3.5 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 31, 2020
Primary Completion (Anticipated)
November 30, 2021
Study Completion (Anticipated)
November 30, 2021
Study Registration Dates
First Submitted
September 19, 2019
First Submitted That Met QC Criteria
September 19, 2019
First Posted (Actual)
September 23, 2019
Study Record Updates
Last Update Posted (Actual)
September 16, 2020
Last Update Submitted That Met QC Criteria
September 11, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-x296
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Chondrosarcoma
-
National Cancer Institute (NCI)Active, not recruitingDedifferentiated Chondrosarcoma | Central Chondrosarcoma, Grade 2 | Central Chondrosarcoma, Grade 3 | Metastatic Clear Cell Sarcoma of Soft Tissue | Metastatic Primary Central Chondrosarcoma | Unresectable Primary Central ChondrosarcomaUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingMesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Clear Cell Chondrosarcoma | Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Primary Central ChondrosarcomaFrance
-
National Cancer Institute (NCI)SuspendedMetastatic Primary Central Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Locally Advanced Unresectable Primary Central ChondrosarcomaUnited States
-
George Clinical Pty LtdGlaxoSmithKlineCompletedChondrosarcoma | Metastatic ChondrosarcomaUnited States, United Kingdom
-
Leiden University Medical CenterCompletedMyxoid Liposarcoma | Mesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Conventional ChondrosarcomaSpain, Netherlands
-
Memorial Sloan Kettering Cancer CenterAgios Pharmaceuticals, Inc.RecruitingChondrosarcoma | IDH1 Gene Mutation | Chondrosarcoma, Grade 2 | Chondrosarcoma, Grade 3United States
-
Italian Sarcoma GroupPharmaMarRecruitingMesenchymal ChondrosarcomaItaly
-
Fred Hutchinson Cancer CenterIncyte CorporationActive, not recruitingRefractory Soft Tissue Sarcoma | Metastatic Leiomyosarcoma | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Advanced Synovial Sarcoma | Metastatic Chondrosarcoma | Advanced Leiomyosarcoma | Metastatic Myxoid... and other conditionsUnited States
-
Istituto Ortopedico RizzoliCompleted
-
Massachusetts General HospitalM.D. Anderson Cancer Center; National Cancer Institute (NCI)Active, not recruitingChordoma of Sacrum | Chordoma of Spine | Chordoma of Base of Skull | Chondrosarcoma of the Spine | Chondrosarcoma of the SacrumUnited States
Clinical Trials on Lattice stereotactic body radiation therapy
-
Washington University School of MedicineCompletedCancer | Palliative RadiotherapyUnited States
-
Memorial Sloan Kettering Cancer CenterVarian Medical SystemsRecruitingMelanoma | Sarcoma | Renal Cell Carcinoma | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Metastatic Solid Tumor | Gastrointestinal Cancer | Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma | Gastrointestinal Adenocarcinoma | Invasive Ductal Breast Carcinoma Stage IV | Lobular... and other conditionsUnited States
-
University of MiamiRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Cancer Prevention Research Institute of TexasActive, not recruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Malignant Neoplasms of Urinary Tract | Oligometastatic Renal Cell CarcinomaUnited States
-
Roswell Park Cancer InstituteCompletedLung CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedPain | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedLung CancerUnited States, Canada
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
Barts & The London NHS TrustBarts Cardiovascular CTU (Queen Mary University of London)Not yet recruitingHypertrophic CardiomyopathyUnited Kingdom
-
Erasmus Medical CenterCompletedKlatskin TumorNetherlands